The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 05, 2019

Filed:

Jan. 15, 2014
Applicant:

Athera Biotechnologies Ab, Stockholm, SE;

Inventors:

Ulf De Faire, Taby, SE;

Johan Frostegård, Stockholm, SE;

Assignee:

ATHERA BIOTECHNOLOGIES AB, Stockholm, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); G01N 33/68 (2006.01); C07K 16/18 (2006.01); C07K 16/44 (2006.01); A61K 47/64 (2017.01);
U.S. Cl.
CPC ...
G01N 33/6854 (2013.01); A61K 39/39583 (2013.01); A61K 47/646 (2017.08); C07K 16/18 (2013.01); C07K 16/44 (2013.01); G01N 33/6893 (2013.01); C07K 2317/52 (2013.01); G01N 2800/323 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. Pharmaceutical compositions comprising a phosphorylcholine conjugate or antibody preparations, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate is proposed as is use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis.


Find Patent Forward Citations

Loading…